Why the study?
Does a heparin-coated cardiopulmonary bypass circuit with reduced systemic heparin improve biocompatibility compared to a noncoated circuit in patients undergoing elective coronary bypass surgery?
Population
20 patients undergoing elective coronary bypass surgery with normal coagulation parameters who did not…
Comparison
Heparin-coated cardiopulmonary bypass circuit… vs Noncoated cardiopulmonary bypass circuit with…
Design
Cohort
Follow-up
postoperatively
Authors
Loading...
Heparin-coated circuits were associated with less C3a rise and platelet loss; leaves open whether reduced systemic heparin is safe in elective CABG.
Does a heparin-coated cardiopulmonary bypass circuit with reduced systemic heparin improve biocompatibility compared to a noncoated circuit in patients undergoing elective coronary bypass surgery?
Heparin-coated cardiopulmonary bypass circuits improve biocompatibility by reducing complement activation and platelet consumption while allowing for a reduced systemic heparin dose.
Horimoto et al. (1996) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: